公开(公告)号：US11707533B2

公开(公告)日：2023-07-25

申请号：US16940326

申请日：2020-07-27

申请人： LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

发明人： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-Na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K47/6849 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2803

摘要： The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US20230405139A1

公开(公告)日：2023-12-21

申请号：US18209299

申请日：2023-06-13

申请人： LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

发明人： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K47/6849 ,  A61P35/00 ,  A61K47/6803 ,  C07K16/2803

摘要： The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US12071483B1

公开(公告)日：2024-08-27

申请号：US16770728

申请日：2018-12-14

申请人： ABL Bio Inc.

发明人： Jinhyung Ahn ,  Sungwon An ,  Dongin Kim ,  Eunsil Sung ,  Jaehyun Eom ,  Sang Hoon Lee ,  Weonkyoo You ,  Juhee Kim ,  Kyungjin Park ,  Hyejin Chung ,  Jinwon Jung ,  Bora Lee ,  Byungje Sung ,  Yeunju Kim ,  Yong-Gyu Son ,  Seawon Ahn ,  Daehae Song ,  Jiseon Yoo ,  Youngdon Pak ,  Donghoon Yeom ,  Yoseob Lee ,  Jaeho Jung

IPC分类号： A61K39/395 ,  A61K47/68 ,  C07K16/18 ,  C07K16/28

CPC分类号： C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

摘要： The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.